

1. That the knowledge gained must be necessary to advance the public's health;

2. There must be no other research model by which the knowledge could be obtained, and the research cannot be ethically performed on human subjects; and

3. The animals used in the proposed research must be maintained either in ethologically appropriate physical and social environments (i.e., as would occur in their natural environment) or in natural habitats.

Based on its deliberations, the IOM committee concluded that "while the chimpanzee has been a valuable animal model in past research, most current use of chimpanzees for biomedical research is unnecessary." The committee generated case studies of predominant areas of chimpanzee research exemplifying the committee's vision for applying the criteria it developed. The case studies concluded that the following areas of the research they assessed may continue to require the use of chimpanzees: some ongoing research on monoclonal antibody therapies, research on comparative genomics, and important studies of social and behavioral factors that affect the development, prevention, or treatment of disease. The committee was unable to reach consensus on the necessity of the chimpanzee for the development of prophylactic hepatitis C virus vaccine. It also acknowledged that new, emerging, or re-emerging diseases may present challenges that may require the use of chimpanzees. To assist the NIH in considering future requests to use chimpanzees in research, the IOM committee provided the set of principles and criteria as a framework to guide NIH's assessment.

In December 2011, NIH accepted the IOM Recommendations (<http://www.nih.gov/news/health/dec2011/od-15.htm>) contained in the report *Chimpanzees in Biomedical and Behavioral Research: Assessing the Necessity* and issued interim policy in notice NOT-OD-12-025, which indicated that NIH would not fund any new or other competing projects (renewal and revisions) for research involving chimpanzees and will not allow any new projects to go forward with NIH-owned or -supported chimpanzees. However, currently funded research was allowed to continue. The policy remains in effect until NIH considers and issues policy implementing the IOM recommendations.

NIH assembled a working group of the NIH Council of Councils on February 1, 2012, to provide advice on

implementation of the IOM recommendations and to consider the size and placement of the active and inactive populations of NIH-owned or -supported chimpanzees. The Working Group was charged with (1) Developing a plan for implementation of the IOM's guiding principles and criteria; (2) Analyzing currently active NIH-supported research using chimpanzees to advise on which studies currently meet the principles and criteria defined by the IOM report and to advise on the process for closing studies if any do not comply with the IOM recommendations; (3) Advising on the size and placement of active and inactive populations of NIH-owned or -supported chimpanzees that may need to be considered as a result of implementing the IOM recommendations; and (4) Developing a review process for considering whether potential future use of the chimpanzee in NIH-supported research is scientifically necessary and consistent with the IOM principles.

The Working Group's efforts culminated in the report containing 28 recommendations to NIH. In developing its recommendations, the Working Group considered public comments received in response to a previous Request for Information ([http://dpcpsi.nih.gov/council/working\\_group.aspx#Summary](http://dpcpsi.nih.gov/council/working_group.aspx#Summary)), considered the scientific use of chimpanzees in currently funded research, obtained advice from external experts, and visited several facilities that house and care for chimpanzees. The Working Group submitted its recommendations and the report to the NIH Council of Councils in open session on January 22, 2013, and the Council of Councils adopted the report. The report is available at [http://dpcpsi.nih.gov/council/working\\_group\\_message.aspx](http://dpcpsi.nih.gov/council/working_group_message.aspx).

*Comments Requested:* The NIH is seeking input on the recommendations from the Council of Councils from the public and the biomedical research community, including foundations, scientific societies, government and regulatory agencies, industry, and NIH grantee institutions. Input is sought for each of the report's recommendations. Response to this RFC is voluntary. Responders are free to address any or all of the recommendations.

Please note that the government will not pay for response preparation or for the use of any information contained in the comments. The NIH may make all comments available, including name of the responder. In addition, NIH may prepare and make available a summary of all input received that is responsive to this RFC.

*How to Submit a Response:* All comments should be submitted electronically to <http://grants.nih.gov/grants/rfi/rfi.cfm?ID=31>. Comments should pertain to the specific recommendation for which feedback is requested and should conform to the word limit indicated. You will see an electronic confirmation acknowledging receipt of your response, but will not receive individualized feedback on any suggestions. No basis for claims against the U.S. government shall arise as a result of a response to this request for information or from the government's use of such information.

Dated: January 28, 2013.

**Lawrence A. Tabak,**  
Principal Deputy Director, National Institutes of Health.

[FR Doc. 2013-02507 Filed 2-4-13; 8:45 am]

BILLING CODE 4140-01-P

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Cancer Institute; Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications\contract proposals and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* National Cancer Institute Special Emphasis Panel; NCI Omnibus Cancer Biology 1.

*Date:* March 11-12, 2013.

*Time:* 8:00 a.m. to 5:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* Doubletree Hotel Bethesda, (Formerly Holiday Inn Select), 8120 Wisconsin Avenue, Bethesda, MD 20814.

*Contact Person:* Zhiqiang Zou, MD, Ph.D., Scientific Review Officer, Special Review and Logistics Branch, Division of Extramural Activities, National Cancer Institute, NIH, 6116 Executive Blvd., Room 8055A, MSC 8329, Bethesda, MD 20892, 301-594-3124, [zouzhiq@mail.nih.gov](mailto:zouzhiq@mail.nih.gov).

*Name of Committee:* National Cancer Institute Special Emphasis Panel; Cancer Immunology.

*Date:* March 15, 2013.

*Time:* 8:00 a.m. to 5:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* Hyatt Regency Bethesda, One Bethesda Metro Center, Bethesda, MD 20814.

*Contact Person:* Delia Tang, MD, Scientific Review Officer, Research Programs Review Branch, Division of Extramural Activities, National Cancer Institute, NIH, 6116 Executive Blvd., Room 8123, MSC 8328, Bethesda, MD 20892, 301-496-2330, [tangd@mail.nih.gov](mailto:tangd@mail.nih.gov).

*Name of Committee:* National Cancer Institute Special Emphasis Panel; Peptide Reagents for Proteomic.

*Date:* March 19, 2013.

*Time:* 8:00 a.m. to 5:00 p.m.

*Agenda:* To review and evaluate contract proposals.

*Place:* Embassy Suites—Old Town Alexandria, 1900 Diagonal Road Alexandria, VA 22314.

*Contact Person:* Marvin L. Salin, Ph.D., Scientific Review Officer, Special Review and Logistics Branch, Division of Extramural Activities, National Cancer Institute, NIH, 6116 Executive Boulevard, Room 7073 Bethesda, MD, 20892-8329, 301-496-0694, [msalin@mail.nih.gov](mailto:msalin@mail.nih.gov).

*Name of Committee:* National Cancer Institute Special Emphasis Panel; Libraries for Reference Standards.

*Date:* March 20, 2013.

*Time:* 8:00 a.m. to 5:00 p.m.

*Agenda:* To review and evaluate contract proposals.

*Place:* Embassy Suites, 1900 Diagonal Road, Alexandria, VA 22314.

*Contact Person:* Marvin L. Salin, Ph.D., Scientific Review Officer, Special Review and Logistics Branch, Division of Extramural Activities, National Cancer Institute, NIH, 6116 Executive Boulevard, Room 7073, Bethesda, MD 20892-8329, 301-496-0694, [msalin@mail.nih.gov](mailto:msalin@mail.nih.gov).

*Name of Committee:* National Cancer Institute Special Emphasis Panel; Wound Healing Materials.

*Date:* March 21, 2013.

*Time:* 8:00 a.m. to 5:00 p.m.

*Agenda:* To review and evaluate contract proposals.

*Place:* Embassy Suites—Old Town 1900 Diagonal Road, Alexandria, VA 22314.

*Contact Person:* Marvin L. Salin, Ph.D., Scientific Review Officer, Special Review and Logistics Branch, Division of Extramural Activities, National Cancer Institute, NIH, 6116 Executive Boulevard, Room 7073, Bethesda, MD 20892-8329 301-496-0694, [msalin@mail.nih.gov](mailto:msalin@mail.nih.gov).

(Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS)

*Dated:* January 30, 2013.

**Melanie J. Gray,**

*Program Analyst, Office of Federal Advisory Committee Policy.*

[FR Doc. 2013-02387 Filed 2-4-13; 8:45 am]

**BILLING CODE 4140-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Cancer Institute; Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The contract proposals and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the contract proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* National Cancer Institute Special Emphasis Panel; Companion Diagnostics.

*Date:* March 18-19, 2013.

*Time:* 8:00 a.m. to 5:00 p.m.

*Agenda:* To review and evaluate contract proposals.

*Place:* Bethesda North Marriott Hotel & Conference Center, Montgomery County Conference Center Facility, 5701 Marinelli Road, North Bethesda, MD 20852.

*Contact Person:* Adriana Stoica, Ph.D., Scientific Review Officer, Special Review and Logistics Branch, Division of Extramural Activities, National Cancer Institute, NIH, 6116 Executive Blvd., Suite 703, Room 7072, Bethesda, md 20892-8329, 301-594-1408, [Stoicaa2@mail.nih.gov](mailto:Stoicaa2@mail.nih.gov).

*Name of Committee:* National Cancer Institute Special Emphasis Panel; Development of Radiation Modulators for Radiotherapy.

*Date:* March 21, 2013.

*Time:* 8:00 a.m. to 6:00 p.m.

*Agenda:* To review and evaluate contract proposals.

*Place:* Bethesda North Marriott Hotel & Conference Center, 5701 Marinelli Road, Bethesda, MD 20852.

*Contact Person:* Viatcheslav A Soldatenkov, MD, Ph.D., Scientific Review Officer, Special Review and Logistics Branch, Division of Extramural Activities, National Cancer Institute, NIH, 6116 Executive Blvd. Room 8057, Bethesda, MD 20892-8329, 301-451-4758, [soldatenkov@mail.nih.gov](mailto:soldatenkov@mail.nih.gov).

*Name of Committee:* National Cancer Institute Special Emphasis Panel; Standards for Metabolomics Research.

*Date:* March 21, 2013.

*Time:* 1:30 p.m. to 4:00 p.m.

*Agenda:* To review and evaluate contract proposals.

*Place:* National Institutes of Health, 6116 Executive Boulevard, Room 6006, Rockville, MD 20852, (Telephone Conference Call).

*Contact Person:* Clifford W. Schweinfest, Ph.D., Scientific Review Officer, Special Review and Logistics Branch, Division of Extramural Activities, National Cancer Institute, NIH, 6116 Executive Blvd., Room 8050A, Bethesda, MD 20892-8329, 301-402-9415, [schweinfestcw@mail.nih.gov](mailto:schweinfestcw@mail.nih.gov).

*Name of Committee:* National Cancer Institute Special Emphasis Panel; Development of Circulating Tumor Cell Devices with Focus on Downstream Single Cell Molecular Analysis.

*Date:* March 26-27, 2013.

*Time:* 8:00 p.m. to 12:00 p.m.

*Agenda:* To review and evaluate contract proposals.

*Place:* Doubletree Hotel Bethesda, (Formerly Holiday Inn Select), 8120 Wisconsin Avenue, Bethesda, MD 20814.

*Contact Person:* Donald L. Coppock, Ph.D., Scientific Review Officer, Special Review and Logistics Branch, Division of Extramural Activities, National Cancer Institute, NIH, 6116 Executive Blvd., Room 7151, Bethesda, MD 20892, 301-451-9385, [donald.coppock@nih.gov](mailto:donald.coppock@nih.gov).

(Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS)

*Dated:* January 30, 2013.

**Melanie J. Gray,**

*Program Analyst, Office of Federal Advisory Committee Policy.*

[FR Doc. 2013-02386 Filed 2-4-13; 8:45 am]

**BILLING CODE 4140-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Institute of Environmental Health Sciences; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The contract proposals and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the contract